$174 Million is the total value of AH Equity Partners Bio II, L.L.C.'s 4 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EQRx, Inc. | $72,021,000 | -39.4% | 17,438,465 | 0.0% | 41.49% | -33.0% | ||
| NAUT | Nautilus Biotechnology, Inc. | $70,733,000 | +334.0% | 16,298,006 | 0.0% | 40.75% | +380.1% | |
| Erasca, Inc. | $21,500,000 | -44.8% | 2,500,000 | 0.0% | 12.39% | -38.9% | ||
| NVTA | InVitae Corporation | $9,326,000 | -47.8% | 1,170,127 | 0.0% | 5.37% | -42.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| EQRx, Inc. | 4 | Q3 2022 | 61.9% |
| Nautilus Biotechnology, Inc. | 4 | Q3 2022 | 40.8% |
| Erasca, Inc. | 4 | Q3 2022 | 20.3% |
| InVitae Corporation | 4 | Q3 2022 | 9.3% |
View AH Equity Partners Bio II, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2023-11-09 |
| 4 | 2023-01-04 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 3 | 2021-12-22 |
| 3 | 2021-06-09 |
View AH Equity Partners Bio II, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.